What is Tonix Pharmaceuticals Holding Sloan Ratio %?
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
As of Mar. 2024, Tonix Pharmaceuticals Holding has a Sloan Ratio of 9.94%, indicating the company is in the safe zone and there is no funny business with accruals.
Tonix Pharmaceuticals Holding Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Tonix Pharmaceuticals Holding's Sloan Ratio %
For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tonix Pharmaceuticals Holding's Sloan Ratio % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Tonix Pharmaceuticals Holding's Sloan Ratio % falls into.
Tonix Pharmaceuticals Holding Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Tonix Pharmaceuticals Holding's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -28.356 (Jun. 2023 ) + -27.975 (Sep. 2023 ) + -27.322 (Dec. 2023 ) + -14.939 (Mar. 2024 ) = $-98.59 Mil.
Tonix Pharmaceuticals Holding's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -23.367 (Jun. 2023 ) + -23.385 (Sep. 2023 ) + -22.34 (Dec. 2023 ) + -17.575 (Mar. 2024 ) = $-86.67 Mil.
Tonix Pharmaceuticals Holding's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was -24.019 (Jun. 2023 ) + -0.821 (Sep. 2023 ) + -0.431 (Dec. 2023 ) + -0.108 (Mar. 2024 ) = $-25.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tonix Pharmaceuticals Holding (NAS:TNXP) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2024, Tonix Pharmaceuticals Holding has a Sloan Ratio of 9.94%, indicating the company is in the safe zone and there is no funny business with accruals.
Tonix Pharmaceuticals Holding Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Tonix Pharmaceuticals Holding's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) Business Description
Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. its portfolio consists of the central nervous system, rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. CNS product candidate is TNX-102 SL, a proprietary sublingual tablet formulation of cyclobenzaprine (CBP) designed for bedtime administration.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TNXP has been successfully added to your 